Shopping Cart 0
Cart Subtotal
USD 0

Novavax Inc (NVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax's clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc (NVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Novavax Amends Co-Development Agreement With PATH 11

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13

Equity Offering 14

Novavax Raises USD57.5 Million in Public Offering of Shares 14

Novavax Plans to Raise USD75 Million in Public Offering of Shares 16

Novavax Raises USD201.2 Million in Public Offering of Common Stock 17

Novavax Raises USD115 Million in Public Offering of Shares 19

Novavax Completes Public Offering Of Shares For USD 100 Million 21

Novavax Completes Private Placement Of Shares For USD 27 Million 22

Novavax Completes Private Placement Of Shares For USD 12.2 Million 23

Debt Offering 24

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Acquisition 26

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Novavax Inc-Key Competitors 28

Novavax Inc-Key Employees 29

Novavax Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Joint Venture 30

Recent Developments 32

Financial Announcements 32

Nov 07, 2018: Novavax reports third quarter 2018 financial results 32

Aug 08, 2018: Novavax Reports second quarter 2018 financial results 34

May 09, 2018: Novavax Reports First Quarter 2018 Financial Results 36

Mar 14, 2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results 37

Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results 40

Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results 41

May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 43

Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 44

Corporate Communications 45

Nov 01, 2018: Novavax appoints Rachel King to Board of Directors 45

Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer 46

Oct 13, 2017: Novavax Announces Leadership Change 47

May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 48

Clinical Trials 49

May 07, 2018: Novavax Reaches Significant Enrollment Milestone in the Prepare Phase 3 Trial of its RSV F Vaccine 49

Apr 02, 2018: Novavax to Present Clinical Data of RSV F Vaccine at World Vaccine Congress 50

Jul 24, 2017: Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs 51

Jul 17, 2017: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM 52

Jun 07, 2017: Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine 53

Jan 19, 2017: Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novavax Amends Co-Development Agreement With PATH 11

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13

Novavax Raises USD57.5 Million in Public Offering of Shares 14

Novavax Plans to Raise USD75 Million in Public Offering of Shares 16

Novavax Raises USD201.2 Million in Public Offering of Common Stock 17

Novavax Raises USD115 Million in Public Offering of Shares 19

Novavax Completes Public Offering Of Shares For USD 100 Million 21

Novavax Completes Private Placement Of Shares For USD 27 Million 22

Novavax Completes Private Placement Of Shares For USD 12.2 Million 23

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Novavax Inc, Key Competitors 28

Novavax Inc, Key Employees 29

Novavax Inc, Other Locations 30

Novavax Inc, Subsidiaries 30

Novavax Inc, Joint Venture 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Novavax Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax's clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc (NVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Novavax Amends Co-Development Agreement With PATH 11

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13

Equity Offering 14

Novavax Raises USD57.5 Million in Public Offering of Shares 14

Novavax Plans to Raise USD75 Million in Public Offering of Shares 16

Novavax Raises USD201.2 Million in Public Offering of Common Stock 17

Novavax Raises USD115 Million in Public Offering of Shares 19

Novavax Completes Public Offering Of Shares For USD 100 Million 21

Novavax Completes Private Placement Of Shares For USD 27 Million 22

Novavax Completes Private Placement Of Shares For USD 12.2 Million 23

Debt Offering 24

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Acquisition 26

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Novavax Inc-Key Competitors 28

Novavax Inc-Key Employees 29

Novavax Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Joint Venture 30

Recent Developments 32

Financial Announcements 32

Nov 07, 2018: Novavax reports third quarter 2018 financial results 32

Aug 08, 2018: Novavax Reports second quarter 2018 financial results 34

May 09, 2018: Novavax Reports First Quarter 2018 Financial Results 36

Mar 14, 2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results 37

Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results 40

Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results 41

May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 43

Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 44

Corporate Communications 45

Nov 01, 2018: Novavax appoints Rachel King to Board of Directors 45

Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer 46

Oct 13, 2017: Novavax Announces Leadership Change 47

May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 48

Clinical Trials 49

May 07, 2018: Novavax Reaches Significant Enrollment Milestone in the Prepare Phase 3 Trial of its RSV F Vaccine 49

Apr 02, 2018: Novavax to Present Clinical Data of RSV F Vaccine at World Vaccine Congress 50

Jul 24, 2017: Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs 51

Jul 17, 2017: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM 52

Jun 07, 2017: Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine 53

Jan 19, 2017: Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novavax Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novavax Amends Co-Development Agreement With PATH 11

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13

Novavax Raises USD57.5 Million in Public Offering of Shares 14

Novavax Plans to Raise USD75 Million in Public Offering of Shares 16

Novavax Raises USD201.2 Million in Public Offering of Common Stock 17

Novavax Raises USD115 Million in Public Offering of Shares 19

Novavax Completes Public Offering Of Shares For USD 100 Million 21

Novavax Completes Private Placement Of Shares For USD 27 Million 22

Novavax Completes Private Placement Of Shares For USD 12.2 Million 23

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Novavax Inc, Key Competitors 28

Novavax Inc, Key Employees 29

Novavax Inc, Other Locations 30

Novavax Inc, Subsidiaries 30

Novavax Inc, Joint Venture 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Novavax Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.